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Amyloid precursor proteinThe abnormal production and accumulation of β-amyloid peptide (Aβ), which is produced from amyloid pre-
cursor protein (APP) by the sequential actions of β-secretase and γ-secretase, are thought to be the initial
causative events in the development of Alzheimer's disease (AD). Accumulating evidence suggests that vas-
cular factors play an important role in the pathogenesis of AD. Speciﬁcally, studies have suggested that one
vascular factor in particular, oxidized low density lipoprotein (oxLDL), may play an important role in regulat-
ing Aβ formation in AD. However, the mechanism by which oxLDL modulates Aβ formation remains elusive.
In this study, we report several new ﬁndings that provide biochemical evidence suggesting that the cardio-
vascular risk factor oxLDL may contribute to Alzheimer's disease by increasing Aβ production. First, we
found that lysophosphatidic acid (LPA), the most bioactive component of oxLDL induces increased produc-
tion of Aβ. Second, our data strongly indicate that LPA induces increased Aβ production via upregulating
β-secretase expression. Third, our data strongly support the notion that different isoforms of protein kinase
C (PKC) may play different roles in regulating APP processing. Speciﬁcally, most PKC members, such as PKCα,
PKCβ, and PKCε, are implicated in regulating α-secretase-mediated APP processing; however, PKCδ, a mem-
ber of the novel PKC subfamily, is involved in LPA-induced upregulation of β-secretase expression and Aβ
production. These ﬁndings may contribute to a better understanding of the mechanisms by which the cardio-
vascular risk factor oxLDL is involved in Alzheimer's disease.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Alzheimer's disease (AD) is characterized clinically by progressive
dementia, including loss of learning and memory. Pathologically, it is
characterized by degeneration of neurons and abnormal protein struc-
tures, including intracellular deposition of neuroﬁbrillary tangles (NFT)
that are composed of themicrotubule-associated protein TAU, and extra-
cellular deposits of various types of β amyloid (Aβ), which is a mix of
peptides that are 39 to 43 amino acids in length. Several lines of evidence
support the hypothesis that progressive accumulation of Aβ is an early
and critical event in the pathogenesis of AD [1]. Studies have revealed
that the accumulation of Aβ initiates a series of downstream neurotoxic
events, including synaptic failure [2] and hyperphosphorylation of TAU,
which results in neuronal dysfunction and death [3]. Aβ is proteolyticallybrillary tangles; Aβ, β amyloid;
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which produces the N-terminus of Aβ, and γ-secretase, which produces
the C-terminus of Aβ [4]. Thus, it is clear that β- and γ-secretases are the
key enzymes in the production of Aβ. Augmented expression of any of
these two secretases or APP itself would result in increased production
of Aβ. β-Secretase (also known as β-site APP cleaving enzyme 1
[BACE1]) has been identiﬁed as a type I membrane aspartyl protease
[5–8]. γ-Secretase is a complex composed of at least four subunits,
namely, presenilin (PS1 or PS2), nicastrin, Aph-1, and Pen-2, of which
presenilin may be the putative catalytic subunit [9].
Recent progress in AD etiology studies suggests that vascular factors
also play an important role in the pathogenesis of AD [10–12]. Speciﬁ-
cally, it has been reported that one vascular factor in particular, oxidized
low density lipoprotein (oxLDL), may play an important role in neuro-
nal cell death in AD [13]. In this regard, post-mortem analyses revealed
that the overall level of oxidative damage to proteins and lipids is
elevated in AD [10,14], and speciﬁcally, cerebrospinal ﬂuid lipoproteins
are more vulnerable to oxidation in AD and are neurotoxic when
oxidized [15]. In this regard, it is also notable that a recent study
revealed a positive correlation between the cerebrospinal ﬂuid (CSF)
levels of Aβ and oxLDL in AD patients, suggesting that oxLDL may
contribute to AD by manipulating Aβ production [16]. Studies have
further shown that lysophosphatidic acid (LPA), the major bioactive
component of oxLDL, can disrupt blood–brain barrier function and
cause AD-related cellular events; for review, see [17]. Interestingly, in
an effort to study the pathogenetic effect of this bioactive component
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cell system. Furthermore, our data also demonstrate that LPA induces
increased expression of β-secretase (BACE1), suggesting that LPA
causes an increase in Aβ production by up-regulating β-secretase
expression. This hypothesis is further supported by our ﬁnding that
LPA induces the activation of the MAPK signaling pathway, which is
known to mediate HNE- and LPA-induced gene expression [18,19]. In
addition, we also found that LPA markedly induces activation (phos-
phorylation) of the transcription factor cAMP response element-
binding protein (CREB) and induces CREB binding activity. Notably,
CREB is one of the possible transcription regulators of the BACE1 gene
[20]. Thus, our novel ﬁnding that components of oxLDL cause increased
production of Aβ opens a new avenue of investigation into the mecha-
nisms by which oxLDL contributes to the development of AD.
2. Materials and methods
2.1. General reagents
Aβ40 and Aβ42 were purchased from American Peptide (Sunnyvale,
CA, USA). Monoclonal antibody 6E10 against Aβ and polyclonal anti-
bodies against Aph1α and Pen- 2 were purchased from COVANCE
(Dedham, MA, USA). Polyclonal antibody anti-nicastrin (NCT) was
purchased from Sigma (St. Louis, MO, USA). Polyclonal antibodies
Anti-PS1N raised against residues 27–50 of PS1 and C15 raised against
the C-terminal 15 residues of human APP have been described previ-
ously [21,22]. The polyclonal antibodies against phospho-MEK,
phospho-ERK, phospho-p90RSK, phospho-CREB, phospho-ATF2,
phospho-PKCα (Ser657), and phospho-PKCδ (Tyr311) were from
Cell Signaling Technology (Danvers, MA, USA). Polyclonal antibodies
against proteins of PKCα and PKCδ and monoclonal antibody against
β-actin were from BD Biosciences (San Jose, CA, USA). Anti-BACE1 anti-
body was from Abcam (Cambridge, MA, USA). LPA (1-oleoyl-2-
hydroxy-sn-glycero- 3-phosphate) was from Avanti Polar Lipids (Ala-
baster, AL, USA). Pertussis toxin (PTX), U0126, and GF109203X were
from Biomol International (Plymouth Meeting, PA, USA). Protein-A
agarose beads and ECL-Plus Western blotting reagents were pur-
chased from Amersham Biosciences (Piscataway, NJ, USA). Phos-
phate buffer was from Sigma (St. Louis, MO, USA). TRIzol reagent
was from Invitrogen (Carlsbad, CA, USA). dCTP-32P was from MP
Biochemicals (Solon, OH, USA), and DNA labeling kit was from GE
Health Care (Piscataway, NJ, USA).
2.2. Cell culture and treatment
The mouse neuroblastoma N2a cell line (WT-7) stably expressing
wild type presenilin 1 (PS1wt) and Swedish mutant APP (APPsw)
were kindly provided by Drs. Sangram S. Sisodia and Seong-Hun Kim
(University of Chicago) and were maintained in DMEM supplemented
with 10% fetal bovine serum, 1% penicillin, and 1% L-glutamine as
described previously [23]. For treatment with LPA, cells were starved
for 24 h in serum-free DMEM and then treated with LPA in fresh
serum-free medium at different concentrations or for a different length
of time as indicated in the each related experiment. Cells were treated
with PTX overnight and kinase inhibitors for 30 min prior to addition
of LPA to examine their effects on the LPA-induced response.
2.3. Immunoprecipitation and Western blot analysis
Immunoprecipitation and Western blot analysis were carried out
as described previously [21]. Secreted Aβ was immunoprecipitated
from conditioned medium (CM) using a monoclonal Aβ-speciﬁc
antibody 6E10 and Protein A beads. The immunoprecipitated Aβ
peptides were analyzed by 13% urea (8 M) SDS–PAGE followed by
Western blotting using 6E10. For detection of other proteins, cells
were lysed in Western blotting lysis buffer (50 mM Tris–HCl, pH6.8, 8 M urea, 5% β-mercaptoethanol, 2% SDS, and protease inhibitor)
and separated by Tris-glycine SDS–PAGE. After being transferred to a
polyvinylidene ﬂuoride membrane (Immobilon-P, Millipore, Billerica,
MA, USA), the blots were probed with speciﬁc antibodies, and the
immunoreactive bands were visualized using the ECL-Plus reagent.2.4. Northern blot analysis
Total RNA of the cells was extracted using TRIzol reagent
(Invitrogen) according to the manufacturer's instructions and subjected
to electrophoresis in formaldehyde-agarose gels. RNA was transferred
onto nylon membranes (Amersham Biosciences) and hybridized with
radiolabeled cDNA probes as described previously [24]. A [α-32P]
dCTP-labeled 685-bp fragment of mouse BACE1 cDNA was used as a
probe to detect mouse BACE mRNA.2.5. Electrophoretic mobility shift assays
Oligonucleotides AGACCATGTAGTTGAGGTCAATGAAGGGGT, AACGG
GCCGGGGGGTGGTGGCACACGCCTT, GGTGTTAACCAATGCTGATTCAGGAA
AGTG, and TGCACTGGCTCCTGCTATGGGTGGGCTCGG containing the
putative CRE, Sp-1, AP-1, and SRE sites of the mouse BACE1 promoter,
respectively, were radiolabeled using [γ-32P] dCTP. Electrophoretic
mobility shift assays (EMSAs) were performed as described previously
[24]. All results presented in this study are representative of at least
three experiments.2.6. Data analysis
All Western blots shown are representative of a minimum of three
independent experiments. For statistical analysis, the density of each
band was quantiﬁed using the Gel Digitizing Software UN-SCAN-IT
(Silk Scientiﬁc, Orem, UT, USA). The ratios of protein levels between
treated samples and controls are expressed as mean±SEM, n=3.
Comparisons between multiple groups were performed by using a
one-way ANOVA with Dunnett posthoc t tests. A single comparison
analysis was made using two-tailed unpaired Student t tests. For
ANOVA or t tests, p values of ≤0.05 or ≤0.01 were considered to be
statistically signiﬁcant. Single and double asterisks indicate signiﬁcant
differences between control and treatment at pb0.05 and 0.01,
respectively.3. Results
3.1. LPA, a bioactive component of oxLDL, induced an increase in Aβ
production
A recent study has shown a positive correlation between CSF levels
of Aβ and oxLDL in AD patients, suggesting oxLDL may have effect on
Aβ production [16]. Studies have further shown that LPA, the major
bioactive component of oxLDL, can disrupt blood–brain barrier function
and cause AD-related cellular events [17]. These observations prompted
us to determine the effect of LPA on the production of Aβ. N2a neuro-
blastoma cells, which stably express PS1wt and myc-tagged APPsw,
have been used in many previous studies for investigating the mecha-
nism of Aβ production [21,23,25]. These cells were starved in a
serum-free medium for 24 h and then treated with LPA. The secreted
Aβwas immunoprecipitated from CMwith 6E10 (COVANCE), a mono-
clonal antibody that recognizes residues 1–17 of Aβ [26], and analyzed
by urea (8 M) SDS–PAGE (13%) followed by Western blot using 6E10.
As shown in Fig. 1, LPA remarkably induced Aβ production in a
dose-dependent manner (top panel), and a peak level of Aβ was
reached at 25 μM LPA.
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protein levels of APP and γ-secretase
Since Aβ is produced from its large precursor APP by the sequential
actions of β-secretase and γ-secretase, enhanced expression of any of
these proteins may lead to increased production of Aβ. Thus, next, we
determined whether treatment with LPA has any effect on the expres-
sion level of APP, β-secretase, and γ-secretase. As shown in Fig. 2a,
when the cells were treatedwith 25 μMof LPA, whichwas shown to in-
duce signiﬁcant increases in Aβ (Fig. 1), LPAwas found to have no effect
on APP expression level in a time course up 24 h (top panel). When
these samples were analyzed for the expression levels of the four
components of γ-secretase (PS1, NCT, Aph-1α, and PEN-2), as shown
in the second to sixth panels, none of these proteins' levels was altered
upon treatmentwith LPA. However,when these sampleswere analyzed
for β-secretase (BACE1), a time-dependent and statistically signiﬁcant
increase in BACE1 protein level was observed (bottom panel of [a] and
bottom panel, right column of [b]). This result strongly suggests that
the LPA-induced increase in Aβ formation is mediated by upregulating
β-secretase expression.
3.3. LPA induced an increase in BACE1 mRNA
Next, we determined whether LPA upregulates BACE1 gene expres-
sion. To do so, starved cells were treated with 25 μM LPA, and the level
of BACE1 mRNA was analyzed by Northern blot assay. As shown inFig 1. LPA induces a dose-dependent increase in Aβ formation. (a) N2a cells were
starved in serum-free medium containing 0.5% serum for 24 h and then treated with
LPA at various concentrations as indicated. Secreted Aβ was immunoprecipitated
from CMwith 6E10 and analyzed by urea (8 M) SDS–PAGE (13%) followed by Western
blot using antibody 6E10. All Western blot data presented in this study are representa-
tives of the results obtained from at least three repeated experiments. (b) Quantitative
analysis of Western blotting signals of secreted Aβ shown in (a). ANOVA identiﬁed a
signiﬁcant induction in secreted Aβ in dose curve experiment. ⁎⁎p≤0.01 vs. untreated
control.Fig. 2c, LPA induced a time-dependent increase in BACE1 mRNA (top
panel). The peak of BACE1 mRNA was observed at the time point of
6 h. The bottom panel shows the levels of 18S and 28S RNA as loading
controls. This data suggest that LPA upregulates BACE1 expression at
the transcriptional level by increasing the expression level of BACE1
mRNA.
3.4. LPA induced increased binding activity of the transcription factor
CREB, but not Sp1, AP-1, and SRF
Sequence analysis revealed that in the promoter region of the BACE1
gene, there are one cAMP responsive element (CRE), one Sp1 site, and
several other transcription factors binding sites, such as AP-1, AP-2,
AP-3, and SRE (serum response element) [27]. To examine whether
these transcription factors play a role in mediating LPA-induced
BACE1 gene expression, we determined the effect of LPA on the binding
activity of these transcription factors to the BACE1promoter by EMSA as
described in our previous study [28]. Nuclear proteins from cells
untreated (0) or treated with 25 μM LPA for indicated times were incu-
bated with radiolabeled oligonucleotides which contain one of the
following possible transcription factor binding sites: CRE site, Sp1 site,
Ap-1 site, and SRE site of the BACE1 promoter for 20 min before loading
onto a 6% TBE acrylamide gel. Interestingly, as shown in Fig. 3, we
observed that the binding activity of CREB to the CRE site of the
BACE1 promoter was signiﬁcantly increased upon LPA stimulation
(top panel). In contrast, the binding activities of Sp1 (second panel),
AP-1 (third panel), and SRE (fourth panel) were not signiﬁcantly
changed. These results suggest that the transcription factor CREB
mediates BACE1 regulation in response to LPA.
3.5. LPA induced activation of intracellular signaling cascades that may
mediate LPA-regulated BACE1 gene expression
LPA has been shown to induce intracellular signaling through the
seven-transmembrane G-protein-coupled receptor (GPCR) called LPA
receptor that is sensitive to pertussis toxin (PTX), which uncouples
GPCR from its Gi/o [29]. To determine the molecular cascades that
lead to LPA-induced BACE1 gene expression, we performed a series of
experiments to determinewhich kinases are activated upon LPA stimu-
lation. Starved cellswere treatedwith 25 μMLPA for different lengths of
time. As shown in the top panel of Fig. 4a, phosphorylated PKCδ was
detected after 15-min treatment with LPA. This membrane was
reprobed with antibody against PKCδ protein to conﬁrm the even
loading of samples (second panel). When the same samples were
analyzed for the activation of other interested molecules, it was found
that, in addition to PKCδ, MEK, MAPK (Erk44/42) and p90RSK were
rapidly phosphorylated in response to LPA. Moreover, the two tran-
scriptional factors, CREB and ATF2 were also rapidly and transiently
phosphorylated. It is notable that both CREB and ATF2 are members of
the ATF/CREB transcription factor family [30]. The phosphorylation of
these transcription factors by LPA treatment is in agreement with the
observation that LPA induced increased CREB binding activity (Fig. 3).
Thus, these results strongly suggest that CREB mediates the up-
regulation of BACE1 expression by LPA. This speculation is also
supported by the observation that p90RSKmediates CREBphosphoryla-
tion in response to activation of upstream PKCδ [31].
3.6. p90RSK is downstream of PKC and MEK
Next, we performed a series of experiments using speciﬁc inhibitors
to further determine the sequential relationship of these cascades. To do
so, cells were pretreatedwith appropriate inhibitors for 30 min prior to
treatmentwith 25 μMLPA for 15 min. As shown in Fig. 5, PTX (lane 3), a
G-protein inhibitor speciﬁc to Gαi, and GF109 (lane 4), a PKC inhibitor,
strongly inhibited the phosphorylation of MEK (top panel), MAPK
(second panel), and p90RSK (third panel), indicating that MEK, MAPK,
Fig. 2. LPA induces increased expression of β-secretase protein. (a) Starved cells were treated with 25 μM LPA for different lengths of time as indicated. Cell lysates collected at each
time point were analyzed by SDS–PAGE followed by Western blotting assay. Top panel was probed with C15 raised against the C-terminal 15 amino acids to determine the level of
full-length APP. Second panel is a blot probed with anti-PS1N to determine the expression level of PS1. Third, fourth, and ﬁfth panels are blots probed with anti-NCT, anti-Aph-1α,
and anti-Pen-2 antibodies, respectively, to determine the expression levels of these proteins. The bottom panel is the blot probed with anti-BACE1 antibody to determine the ex-
pression level of β-secretase. NCTm and NCTim indicate the mature and immature forms of Nicastrin. (b) Quantitative analysis of Western blotting signals shown in (a) identiﬁed a
signiﬁcant induction of BACE1 but not of components of γ-secretase or APP. ⁎p≤0.05; ⁎⁎p≤0.01 vs. untreated control. (c) LPA induction of BACE1 mRNA. Starved cells were treated
with 25 μM LPA. At the time points indicated, total RNA was isolated, and Northern blot analysis was performed using mouse BACE1 cDNA as a probe as described in our previous
study [19]. Visualized bands of 28S and 18S ribosomal RNA served as loading controls.
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G-protein and PKC. In addition, when the cells were treated with
U0126, anMEK-speciﬁc inhibitor, as shown in lane 5, U0126 completely
inhibited the activation of MAPK (second panel) and p90RSK (third
panel), indicating that activation of MEK is required for activation of
MAPK and p90RSK stimulated by LPA. These results indicate that
p90RSK is downstream of PKC and MEK. The bottom panel is the
reprobe of the membrane in the second panel with an antibody against
Erk44/42 protein to conﬁrm the even loading of the samples.
3.7. PKC inhibitor GF attenuated LPA-induced increase in Aβ formation
The data presented above strongly suggest that PKC is an upstream
effector in the LPA-induced intracellular signaling cascades that maymediate LPA-induced increase in Aβ formation. Thus, we performed an
experiment to determine the effect of PKC inhibitor on LPA-induced Aβ
formation. To do so, cells were pretreated with PKC inhibitor
GF109203X for 30 min prior to treatment with 25 μM LPA for 24 h.
After treatment with LPA for 24 h, Aβ was immunoprecipitated from
the CMwith 6E10 and analyzed byurea (8 M) SDS–PAGE (13%) followed
by Western blot using 6E10. As shown in the top panel of Fig. 6a,
GF109203X dose-dependently and statistically signiﬁcantly inhibited
LPA-induced Aβ formation (compare lanes 4, 5, and 6 with lane 3 in [a]
and as indicated in the upper panel in [b]). It was also noted that, at a
high concentration (5 μM), GF109203X also strongly inhibited the
basal level of Aβ formation (compare lane 2with lane 1). Next, we deter-
mined the effect of GF109203Xon LPA-induced expression of BACE1. The
cell lysates from the above dose-curve experiment were analyzed by
Fig. 3. Time course of LPA-induced increase in binding activity of transcriptional factor
CREB. LPA-induced binding activities of various transcription factors were analyzed by
EMSA. Nuclear proteins from cells untreated (0) or treated with 25 μM LPA for indicat-
ed times were incubated with radiolabeled oligonucleotides that contain one of the fol-
lowing possible transcription factor binding sites of BACE1 promoter for 20 min: CRE
site (top panel), Sp1 site (second panel), Ap-1 site (third panel), and SRE site (bottom
panel). Then, proteins were separated by a 6% TBE acrylamide gel. The protein-nucleic
acid complexes were determined by autoradiography of 32P-labeled nucleic acid.
Fig. 4. Time course of LPA-induced activation of signaling cascades. N2a cells were
stimulated with 25 μM LPA, and, at the time points indicated, cell lysates were ana-
lyzed by 10% SDS–PAGE and transferred to a PVDF membrane. Phosphorylated PKCδ
(top panel), MEK1/2 (third panel), MAPK (Erk44/42, fourth panel), p90RSK (ﬁfth
panel), CREB (sixth panel), and ATF2 (seventh panel) were detected with antibodies
against phospho-MEK1/2 (P-MEK1/2) (Ser217/221), phospho-MAPK (P-Erk44/42,
Thr202/Tyr204), and phospho-p90RSK (P-p90RSK, Ser381), phosphor-CREB (p-CREB),
and phosphor-ATF2 (p-ATF-2), respectively (Cell Signaling Technology). The membranes
in the top panel were stripped and re-probed with anti-PKCδ antibody to ensure equal
loading. (a) Representative of three repeated Western blot results; (b) quantiﬁcation
and statistical analysis of the western blot results shown in (a).
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middle panel of (a) and the lower panel of (b), GF109203X caused a
dose-dependent and statistically signiﬁcant decrease in LPA-induced
BACE1 expression (compare lanes 4, 5, and 6 with lane 3). Interestingly,
it was found that, at a high concentration (5 μM), GF also strongly
inhibited the basal level of BACE1 expression (compare lane 2 with
lane 1). These results strongly suggest that the inhibitory effect of GF
on Aβ formation is mediated by inhibition of BACE1 expression.
3.8. Overexpression of PKCδ caused an increase in Aβ production
As shown in Fig. 4, our data show that LPA induces PKCδ activation.
To further determine the possible role of PKCδ in LPA-induced Aβ
production, we examined the effects of overexpression of wild type
PKCδ (PKCδ[wt]) and dominant negative mutant PKCδ (PKCδ[DN]) on
Aβ production. As controls, wild type PKCα (PKCα[wt]) and dominant
negative mutant PKCα (PKCα[DN]) were also included in these exper-
iments. The adenovirus system has been successfully used to deliver
genes [high efﬁciency (99%)] into cultured cells [32–34]. Cells were
infected with recombinant adenovirus expressing these PKC variants
as described in our previous study [35]. Twenty-four hours after infec-
tion, secreted Aβ was immunoprecipitated from conditioned media
with 6E10 and analyzed by Western blot using 6E10. Cell lysates were
analyzed for the expression of PKC. As shown in Fig. 6c, both PKCα
and PKCδwere overexpressed in virus-infected cells (top panel). No dif-
ferences in the Aβ levels were detected in cells expressing wild type
PKCα and dominant negative PKCα in comparisonwith cells expressing
non-related protein LacZ (compare lanes 2 and 3 with lane 1 in the
middle panel). Interestingly, an increase in Aβ production was detected
in cells expressing wild type PKCδ (compare lane 4 with lanes 1). In
contrast, a slightly decrease in Aβ production was detected in cells
expressing dominant negative mutant PKCδ (compare lane 5 with
lane 1). Quantiﬁcation of the Western blotting signals indicates the
increase in Aβ caused by overexpression of PKCδ is statistically signiﬁ-
cant (d). These data suggest that PKCδ plays a role in regulating Aβ
formation.4. Discussion
LPA is one of the most bioactive components of oxLDL and has
been found to be a major risk factor for cardiovascular disease [36].
LPA has also been implicated in AD development by many recent
studies, for review see [17]. LPA is present in several biological ﬂuids
(serum, plasma, aqueous humor) [37]. As a component of oxLDL, LPA
can be formed by mild oxidization of LDL [36] and synthesized and
released by several cell types (platelets, ﬁbroblasts, adipocytes,
cancer cells) [37]. The key enzyme that governs the synthesis of LPA
is lysophospholipase D (lysoPLD), which is identical to autotaxin, a
tumor cell motility-stimulating factor [29]. In this regard, it is notable
that a recent study revealed that autotaxin expression is enhanced in
frontal cortex of AD patients, suggesting that autotaxin and its
product LPA may be involved in AD pathology [38]. Interestingly, in
an effort to study the pathogenetic effect of oxLDL, our data revealed
that LPA, the major bioactive component of oxLDL, can enhance Aβ
production. This result prompted us to further determine the mecha-
nism by which LPA upregulates Aβ production. Since Aβ peptide is
produced from its precursor APP, we ﬁrst examined whether LPA
treatment has any effect on APP expression. Our data revealed that
LPA treatment has no effect on APP expression under our experimental
conditions. There are two enzymes that play key roles in APP processing
and Aβ production, the β-secretase, which produces the N-terminal of
Aβ, and γ-secretase, which produces the C-terminal of Aβ [9]. Next,
we determined the effect of LPA on the expression levels of these
secretases. Our results demonstrated that LPA treatment had no effect
on the expression levels of the four components of γ-secretase, PS1,
NCT, Aph-1α, and Pen-2. However, our time course experiments clearly
showed that LPA induced an increase in the expression level of
β-secretase, BACE1. These results strongly suggest that LPA causes an
Fig. 4 (continued).
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ﬁnding also suggests that oxLDL may contribute to Alzheimer's disease,
at least in part, via upregulating β-secretase expression and Aβ forma-
tion. In support of our ﬁndings, HNE, the other component of oxLDL,
has been recently shown to induce the expression and activity of
BACE1 [39]. Moreover, a recent study has shown that oxidative stress
elevatesβ-secretase protein and activity in vivo in an animalmodel [40].
Our data further suggest that LPA upregulates BACE1 expression at
the transcriptional level by increasing the expression level of BACE1mRNA. DNA sequence analysis of the promoter region of BACE1 gene
has revealed that there are one CRE site, one Sp1 site, and several
other transcription factor binding sites, such as AP-1, AP-2, AP-3, and
SRE sites [27]. It was also reported that overexpression of the transcrip-
tion factor Sp1 potentiates BACE gene expression [27]. To determine
which transcriptional factor is responsible for LPA-induced BACE1
expression, we carried out a gel-shift experiment, and our results
revealed that the binding activity of CREB to the CRE site of the BACE1
promoter was signiﬁcantly increased upon LPA treatment, while the
Fig. 5. Effect of PTX, GF109, and U0126 on the activation of MEK (top panel), MAPK (second panel), and p90RSK (third panel). N2a cells were pretreated with 100 ng/ml pertussis
toxin for 16 h or pretreated with 5 μM GF109 or 10 μM U0126 for 30 min prior to the addition of 25 μM LPA for 15 min. The cell lysates were analyzed as described in Fig. 4. The
membranes of the second panel were stripped and re-probed with anti-Erk antibody to ensure equal loading. (a) Representative of three repeated Western blot results; (b) quan-
tiﬁcation and statistical analysis of the western blot results shown in (a).
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indicate that BACE1 expression can be regulated by different transcrip-
tional factors under different conditions. Our results that LPA treatment
resulted in an increased binding activity of CREB to the BACE1 promoter
suggest that in response to LPA stimulation, it is CREB, but not Sp1,
AP_1, or SRE, that mediates the upregulation of BACE1 expression.
This notion is further strongly supported by our ﬁndings that LPA
induced the activation of a series of intracellular signaling cascades
that led to the activation of CREB. Our results revealed that LPA induced
activation of PKC, MEK, MAPK, and p90RSk with PKC as the mostupstream and p90RSK as the most downstream elements in the
LPA-induced signaling cascades, which are sensitive to PTX, a speciﬁc
inhibitor of certain G proteins. Given the fact that p90RSK has been
reported to mediate CREB phosphorylation in response to activation of
upstream PKCδ [31], as summarized in Fig. 7, our data strongly suggest
that LPA-induced BACE1 promoter activation is mediated by PKCδ-
MEK-MAPK-p90RSK-CREB signaling cascades.
Previous studies have shown that PKC is involved in regulation of
α-secretase-mediated APP processing, and speciﬁcally, in up-regulation
of the secretion of sAPPα generated by α-secretase [41–44]. Studies
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Fig. 7. A schematic summary of the molecular pathway by which LPA induces Aβ
production.
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regulating α-secretase-mediated APP processing [45–47]. In some types
of cells, PKCα and PKCβ isoforms may also be involved in the regulation
ofα-secretase-mediated APP processing [45,48], but PKCδ is not involved
[47,49]. These studies suggest a possibility that PKC may indirectly
regulate Aβ formation by promoting α-secretase-mediated processing
of APP. However, whether PKC has any direct regulatory effect on Aβ
formation remains unclear. In this study, we examined the effects of
these PKC isoforms on Aβ formation. As a result, our data revealed, for
the ﬁrst time, that overexpression of PKCδ, but not PKCα, leads to
increased production of Aβ. This ﬁnding provided further strong support
to our notion that PKCδ functions as an important upstreameffector in the
LPA-induced intracellular pathway that leads to the activation of the
BACE1 promoter and increased expression of β-secretase and eventually
results in an increase in the production of Aβ as discussed above. Given
the fact that previous studies have shown that activation of PKCδ, unlike
PKCα and PKCε, has no effect on α-secretase-mediated APP processing,
our data suggest that PKCδ may speciﬁcally be involved in β-secretase-
mediated APP processing.
In conclusion, the data presented in this study clearly indicate that
LPA, themost bioactive component of oxLDL, induces increased produc-
tion of Aβ. Furthermore, our data indicate that LPA induces increased Aβ
production via upregulating β-secretase expression. In addition, our
data strongly support the notion that different isoforms of PKC may
play different roles in regulating APP processing, and speciﬁcally that,
different from most other PKC members, such as PKCα, PKCβ, and
PKCε, which are implicated in regulating α-secretase-mediated APP
processing, PKCδ, a member of the novel PKC subfamily, is involved in
LPA-induced upregulation of β-secretase expression and Aβ produc-
tion. These ﬁndings provide biochemical evidence that suggests that
the cardiovascular risk factor LPA, a major bioactive lipid componentFig. 6. PKCδ regulates Aβ production. (a) PKC inhibitor GF109203X (GF) blocks LPA-induced A
various concentrations for 30 min and then treated with LPA at indicated concentrations for
urea SDS–PAGE followed byWestern blotting using 6E10. BACE1 expression was determined b
brane in the secondwith anti-β-actin to ensure even loading of the samples. Lane 7 is the Aβ40
(a) were quantiﬁed, and the control and LPA-treated samples comparedwith GF-treated sampl
with recombinant adenovirus-expressing PKC variants, cell lysates were separated by 10% SDS
(top panel, Cell Signaling Technology). (d) Quantiﬁcation and statistical analysis of theWester
panel is the reprobe of the membrane in the top panel for β-actin. Statistical signiﬁcances wer
indicated: ⁎⁎p≤0.01.of oxLDL, may contribute to AD by increasing Aβ production and that
different isoforms of PKC may regulate APP processing and Aβ produc-
tion in different ways.Acknowledgments
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